Online inquiry

IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12373MR)

This product GTTS-WQ12373MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SAA1 gene. The antibody can be applied in AA amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000331.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6288
UniProt ID P0DJI8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12373MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9526MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ6382MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ15053MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ1658MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACT-017
GTTS-WQ7800MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ3959MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ13180MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ6391MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW